


WHAT IS CLAIMED IS:

1. A compound of the Formula A:



5 wherein:

a is 0 or 1; b is 0 or 1; m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 0, 1 or 2; q is 0, 1, 2 or 3; r is 0 or 1; s is 0 or 1; t is 2, 3, 4, 5 or 6;

- 10  $R^1$  is independently selected from: 1)  $(C=O)_aO_bC_1-C_{10}$  alkyl, 2)  $(C=O)_aO_b$ aryl, 3)  $C_2-C_{10}$  alkenyl, 4)  $C_2-C_{10}$  alkynyl, 5)  $(C=O)_aO_b$  heterocyclyl, 6)  $(C=O)_aO_bC_3-C_8$  cycloalkyl, 7)  $CO_2H$ , 8) halo, 9) CN, 10) OH, 11)  $O_bC_1-C_6$  perfluoroalkyl, 12)  $O_a(C=O)_bNR^6R^7$ , 13)  $NR^c(C=O)NR^6R^7$ , 14)  $S(O)_mR^a$ , 15)  $S(O)_2NR^6R^7$ , 16)  $NR^cS(O)_mR^a$ , 17) oxo, 18) CHO, 19)  $NO_2$ , 20)  $NR^c(C=O)O_bR^a$ , 21)  $O(C=O)O_bC_1-C_{10}$  alkyl, 22)  $O(C=O)O_bC_3-C_8$  cycloalkyl, 23)  $O(C=O)O_b$ aryl, 24)  $O(C=O)O_b$ -heterocycle, and 25)  $O_a-P=O(OH)_2$ , said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from  $R^Z$ ;

- 20  $R^2$  is independently selected from: 1)  $(C=O)_aO_bC_1-C_{10}$  alkyl, 2)  $(C=O)_aO_b$ aryl, 3)  $C_2-C_{10}$  alkenyl, 4)  $C_2-C_{10}$  alkynyl, 5)  $(C=O)_aO_b$  heterocyclyl, 6)  $(C=O)_aO_bC_3-C_8$  cycloalkyl, 7)  $CO_2H$ , 8) halo, 9) CN, 10) OH, 11)  $O_bC_1-C_6$  perfluoroalkyl, 12)  $O_a(C=O)_bNR^6R^7$ , 13)  $NR^c(C=O)NR^6R^7$ , 14)  $S(O)_mR^a$ , 15)  $S(O)_2NR^6R^7$ , 16)  $NR^cS(O)_mR^a$ , 17) CHO, 18)  $NO_2$ , 19)  $NR^c(C=O)O_bR^a$ , 20)  $O(C=O)O_bC_1-C_{10}$  alkyl, 21)  $O(C=O)O_bC_3-C_8$  cycloalkyl, 22)  $O(C=O)O_b$ aryl, 23)  $O(C=O)O_b$ -heterocycle, and 24)  $O_a-P=O(OH)_2$ , said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from  $R^Z$ ;

- 25  $R^3$  and  $R^4$  are independently selected from: H,  $C_1-C_6$ -alkyl and  $C_1-C_6$ -perfluoroalkyl, or

R<sup>3</sup> and R<sup>4</sup> are combined to form -(CH<sub>2</sub>)<sub>t</sub>- wherein one of the carbon atoms is optionally replaced by a moiety selected from O, S(O)<sub>m</sub>, -N(R<sup>b</sup>)C(O)-, and -N(COR<sup>a</sup>)-;

R<sup>5</sup> is independently selected from: 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl, 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl, 3) C<sub>2</sub>-C<sub>10</sub> alkenyl, 4) C<sub>2</sub>-C<sub>10</sub> alkynyl, 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl, 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl, 7) CO<sub>2</sub>H, 8) halo, 9) CN, 10) OH, 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>6</sup>R<sup>7</sup>, 13) NR<sup>c</sup>(C=O)NR<sup>6</sup>R<sup>7</sup>, 14) S(O)<sub>m</sub>R<sup>a</sup>, 15) S(O)<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>, 17) oxo, 18) CHO, 19) NO<sub>2</sub>, 20) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl, 21) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl, and 22) O<sub>a</sub>-P=O(OH)<sub>2</sub>, said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>z</sup>;

R<sup>6</sup> and R<sup>7</sup> are independently selected from: 1) H, 2) (C=O)O<sub>b</sub>R<sup>a</sup>, 3) C<sub>1</sub>-C<sub>10</sub> alkyl, 4) aryl, 5) C<sub>2</sub>-C<sub>10</sub> alkenyl, 6) C<sub>2</sub>-C<sub>10</sub> alkynyl, 7) heterocyclyl, 8) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, 9) SO<sub>2</sub>R<sup>a</sup>, 10) (C=O)NR<sup>b</sup>, 11) OH, and 12) O<sub>a</sub>-P=O(OH)<sub>2</sub>, said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>z</sup>;

R<sup>z</sup> is selected from: 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl, 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl, 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>, 4) oxo, 5) OH, 6) halo, 7) CN, 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl, 9) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl, 10) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, 11) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl, 12) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl, 13) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>, 14) C(O)R<sup>a</sup>, 15) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>R<sup>a</sup>, 16) C(O)H, 17) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H, 18) C(O)N(R<sup>b</sup>)<sub>2</sub>, 19) S(O)<sub>m</sub>R<sup>a</sup>, 20) S(O)<sub>2</sub>N(R<sup>b</sup>)<sub>2</sub>, 21) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>, 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl, 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl, 24) O(C=O)O<sub>b</sub>aryl, 25) O(C=O)O<sub>b</sub>-heterocycle, and 26) O<sub>a</sub>-P=O(OH)<sub>2</sub>, said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, N(R<sup>b</sup>)<sub>2</sub> and O<sub>a</sub>-P=O(OH)<sub>2</sub>;


R<sup>a</sup> is: substituted or unsubstituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, substituted or unsubstituted (C<sub>2</sub>-C<sub>6</sub>)alkenyl, substituted or unsubstituted (C<sub>2</sub>-C<sub>6</sub>)alkynyl, substituted or unsubstituted (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, substituted or unsubstituted aryl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl;

R<sup>b</sup> is: H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>; and

$R^C$  is selected from: 1) H, 2) C<sub>1</sub>-C<sub>10</sub> alkyl, 3) aryl, 4) C<sub>2</sub>-C<sub>10</sub> alkenyl, 5) C<sub>2</sub>-C<sub>10</sub> alkynyl, 6) heterocyclyl, 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, and 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $R^Z$ ;

5 or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The compound according to Claim 1 of the Formula B:



wherein:


10

$R^{Z'}$  is selected from: alkyl, cycloalkyl, aryl and heterocyclyl, said alkyl, cycloalkyl, aryl or heterocyclyl is optionally substituted with 1 to 3  $R^Z$ ;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

15

3. The compound according to Claim 2 of the Formula C:



20 wherein:

R<sup>6</sup> is selected from: H and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

5                      4. A compound which is selected from:

**5-phenyl-6-[4-({[4-(1,2,3-thiadiazol-4-yl)benzyl]amino}methyl)phenyl]nicotinonitrile;**

**5-phenyl-6-[4-({[(1S,2R)-2-phenylcyclopropyl]amino}methyl)phenyl]nicotinonitrile:**

6-(4-{[(3,4-difluorobenzyl)amino]methyl}phenyl)-5-phenylnicotinonitrile;

10 6-[4-({[2-(3-fluorophenyl)ethyl]amino}methyl)phenyl]-5-phenylnicotinonitrile;

**6-[4-({[2-(4-fluorophenyl)ethyl]amino}methyl)phenyl]-5-phenylnicotinonitrile:**

**5-phenyl-6-[4-({[(4-phenylmorpholin-2-yl)methyl]amino}methyl)phenyl]nicotinonitrile;**

6-[4-({[(4-benzylmorpholin-2-yl)methyl]amino}methyl)phenyl]-5-phenylnicotinonitrile;

6-[4-({methyl[(1-phenyl-1H-pyrazol-4-yl)methyl]amino}methyl)phenyl]-5-phenylnicotinonitrile;

15 N-[2-(1-methylpyrrolidin-2-yl)ethyl]-N-{4-[3-phenyl-5-(1H-tetrazol-5-yl)pyridin-2-yl]benzyl}amine;

1-{4-[3-phenyl-5-(1H-tetrazol-5-yl)pyridin-2-yl]phenyl}-N-[4-(1,2,3-thiadiazol-4-yl)benzyl]methanamine;

**N-(3,4-difluorobenzyl)-N-{4-[3-phenyl-5-(1H-tetrazol-5-yl)pyridin-2-yl]benzyl}amine:**

2-chloro-5-phenyl-6-[4-( {[4-(1,2,3-thiadiazol-4-yl)benzyl]amino }methyl)phenyl] nicotinonitrile;

20 1-(2-Aminophenyl)-3-({4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}amino)propan-  
1-one;

3-({4-[5-cyano-3-phenylpyridin-2-yl]benzyl}amino)-1-phenylpropan-1-one; and

3-({4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}amino)-1-phenylpropan-1-one;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

25

5. The TFA salt of a compound according to Claim 1 which is:

5-phenyl-6-[4-({[4-(1,2,3-thiadiazol-4-yl)benzyl]amino}methyl)phenyl]nicotinonitrile;

5-phenyl-6-[4-({[(1S,2R)-2-phenylcyclopropyl]amino}methyl)phenyl]nicotinonitrile;

30 6-(4-{[(3,4-difluorobenzyl)amino]methyl}phenyl)-5-phenylnicotinonitrile;

6-[4-({[2-(3-fluorophenyl)ethyl]amino}methyl)phenyl]-5-phenylnicotinonitrile;

6-[4-({[2-(4-fluorophenyl)ethyl]amino}methyl)phenyl]-5-phenylnicotinonitrile;

**5-phenyl-6-[4-({[(4-phenylmorpholin-2-yl)methyl]amino)methyl}phenyl]nicotinonitrile;**

6-[4-({[(4-benzylmorpholin-2-yl)methyl]amino}methyl)phenyl]-5-phenylnicotinonitrile;

35 6-[4-({methyl[(1-phenyl-1H-pyrazol-4-yl)methyl]amino }methyl)phenyl]-5-phenylnicotinonitrile;

N-[2-(1-methylpyrrolidin-2-yl)ethyl]-N-{4-[3-phenyl-5-(1H-tetrazol-5-yl)pyridin-2-yl]benzyl}amine;  
1-{4-[3-phenyl-5-(1H-tetrazol-5-yl)pyridin-2-yl]phenyl}-N-[4-(1,2,3-thiadiazol-4-yl)benzyl]methanamine;

N-(3,4-difluorobenzyl)-N-{4-[3-phenyl-5-(1H-tetrazol-5-yl)pyridin-2-yl]benzyl}amine;

5 1-(2-Aminophenyl)-3-({4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}amino)propan-1-one; and

3-({4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}amino)-1-phenylpropan-1-one;

or a stereoisomer thereof.

10

6. A compound according to Claim 4 which is:

1-(2-Aminophenyl)-3-({4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}amino)propan-1-one;

15

or a pharmaceutically acceptable salt or a stereoisomer thereof.

7. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

20

8. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 4.

25

9. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.

10. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 4.

30

11. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

12. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 4.

35

13. A method for treating a non-malignant disease in which angiogenesis is implicated which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

5 14. A method for treating a non-malignant disease in which angiogenesis is implicated which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 4.

10 15. The composition of Claim 8 further comprising a second compound selected from: 1) an estrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic/cytostatic agent, 5) an antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) an HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor, 10) an angiogenesis inhibitor, 11) a PPAR- $\gamma$  agonist, 12) a PPAR- $\delta$  agonist, 13) an inhibitor of cell proliferation and survival signaling, and 14) an agent that interferes with a cell cycle checkpoint.

15 16. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

20 17. A method of treating hyperproliferative disorders selected from restenosis, inflammation, autoimmune diseases and allergy/asthma which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

25 18. A method of treating hyperinsulinism which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.